GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: JAMA Internal Medicine, American Medical Association (AMA), Vol. 176, No. 6 ( 2016-06-01), p. 816-
    Type of Medium: Online Resource
    ISSN: 2168-6106
    Language: English
    Publisher: American Medical Association (AMA)
    Publication Date: 2016
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 3625-3625
    Abstract: Background. Human papillomavirus (HPV) infection, in particular HPV16, is causing an increasing number of oropharyngeal cancers in Europe and the United States. HPV16 E6 antibodies are a marker of tumour integration and would be expected to be present among cases with a HPV related tumour but absent or very low in individuals without a HPV related cancer. We investigated the presence of HPV16 E6 antibodies in two large European studies - (i) a retrospective case-control study of 1219 cases (366 oral cavity, 324 oropharynx and 529 hypopharynx/larynx) and 1425 controls with blood samples collected at the time of diagnosis among the cases (the ARCAGE study), and (ii) a nested case-cnotrol study of 638 incident head and neck cancers (including 180 oral, 135 oropharynx, and 247 hypopharynx/larynx), and 1599 comparable controls from the EPIC cohort study, with blood samples collected between 1 and 14 years before diagnosis among the cases. Methods. Plasma from all cases and controls was analyzed for antibodies against multiple proteins of HPV16, with a particular focus on HPV16 E6. Odds ratios (OR) of cancer and 95% confidence intervals (CI) were calculated adjusting for potential confounders. All-cause mortality was evaluated among cases using Cox proportional hazards regression. Findings. Within ARCAGE, HPV16 E6 seropositivity was present in 0.8% (11/1425) of controls and 30.2% (97/324) of oropharynx cases (OR=132.0, 95% CI 65-266). A much weaker association was also seen for larynx cancer (8/529 cases positive; OR=4.2 95%CI 1.5-11.3). No association was seen for oral cancer (4/366 cases positive; OR=1.9 95% CI 0.6-6.2). Within the EPIC nested case-control study 34.8% of oropharyngeal cancer cases and 0.6% of controls were HPV16 E6 positive (OR= 274, 95% CI 110 to 681), although no association was seen with other cancer sites. The increased risk of oropharyngeal cancer among HPV16 E6 seropositive participants was independent of time between blood collection and diagnosis and was observed more than 10 years before diagnosis. Interpretation. Our results indicate that (i) HPV16 E6 antibodies are rare in controls, and less than 1%, (ii) about 30% of oropharynx cancer cases are positive for HPV16, with blood samples taken at the time of diagnosis, and (iii) HPV16 E6 seropositivity is present more than 10 years prior to diagnosis of oropharyngeal cancers. Further, because of its near absence in controls, it may potentially be useful as a biomarker for early detection of oropharyngeal cancer that is presumably HPV-positive. Citation Format: Paul Brennan, Mattias Johannson, Devasena Anantharaman, Michael Pawlita, Aimee Kreimer, on behalf of the EPIC and ARCAGE study groups. An analysis of human papilloma virus (HPV) E6 antibodies and risk of head and neck cancer: two large European studies. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3625. doi:10.1158/1538-7445.AM2013-3625
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 77, No. 13_Supplement ( 2017-07-01), p. 4238-4238
    Abstract: Metabolomics is a systems approach to the biology of health and disease and an ‘-omics’ discipline that measures small metabolites representing end products of a variety of metabolic and cellular processes as reflected in available biological specimens (e.g. blood, urine, saliva, feces and tissue). As an increasingly more common approach used for epidemiologic and clinical studies, metabolomics has the potential to improve disease risk assessment, screening, diagnosis, prognosis and predictive response to therapy, as well as provide disease mechanistic insight and help to establish criteria for causation. It is timely to establish mechanisms for leveraging existing resources and data for novel biomarker discovery using metabolomics approaches. To this end, the National Institutes of Health COnsortium of METabolomics Studies (COMETS) was established in 2014 (http://epi.grants.cancer.gov/comets/), and currently includes 34 prospective cohorts and 2 consortia from the United States, Europe, Asia and South America. The COMETS mission is to promote collaborations among prospective cohort studies that follow participants for a range of outcomes and perform metabolomic profiling of individuals. COMETS aims to facilitate an open exchange of ideas, knowledge, and results to accelerate a shared goal of identifying metabolomic profiles associated with chronic disease phenotypes (e.g. heart disease, diabetes, cancer). The structure of COMETS includes a steering committee with one representative from each participating cohort/consortium and a number of working groups, including age analysis, data harmonization, statistics, and trainee. In November 2016, COMETS held their inaugural scientific meeting. As a result of this meeting, more working groups are currently being established to support additional interests/projects among the consortium members. Here we further describe the COMETS structure, including preliminary descriptive data, which aims to advance the use and impact of metabolite profiling in population-based research. Citation Format: Rachael Z. Stolzenberg-Solomon, Steven Moore, Crnelia Ulrich, Elizabeth Poole, Marinella Temprosa, Mukesh Verma, Demetrius Albanes, Clara Barrios Barrera, Eric Boerwinkle, Juan P. Casas, Clary Clish, Robert Gerszten, Christian Gieger, Marc Gunter, Sei Harada, Tamara Harris, David Herrington, Ann Hsing, Mattias Johannson, Claudia Langenberg, Jessica Lasky-Su, Loic Le Marchand, Charles Matthews, Cristina Menni, Matej Oresic, Eric Orwoll, Alexandre Pereira, Kathyrn Rexrode, Svati Shah, Xiao-ou Shu, Victoria Stevens, Bing Yu, Hua Zhao, Krista Zanetti. COnsortium for METabolomics Studies (COMETS): leveraging resources to accelerate scientific discovery [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4238. doi:10.1158/1538-7445.AM2017-4238
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2017
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: The Journal of Nutrition, Elsevier BV, Vol. 153, No. 7 ( 2023-07), p. 2051-2060
    Type of Medium: Online Resource
    ISSN: 0022-3166
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2023
    detail.hit.zdb_id: 1469429-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...